Trial Profile
An Ascending Single Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics / Pharmacodynamics Of PF-05280602, A Recombinant Factor VIIa Variant (813d), In Adult Hemophilia A And B Subjects With Or Without Inhibitors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Marzeptacog alfa (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Catalyst Biosciences
- 29 Jun 2020 According to a Catalyst Biosciences media release, data from this trial will be presented at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress being held from July 12-14, 2020.
- 01 Aug 2019 According to a Catalyst Biosciences media release, the company plans to report data from this trial in 2020.
- 04 Sep 2018 Results presented in the Catalyst Biosciences media release.